Delving into the Latest Updates on Vedolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Kynteles, Vedolizumab (Genetical Recombination), Vedolizumab (genetical recombination) (JAN)

+ [16]

Target

α4β7

Action

antagonists

Mechanism

α4β7 antagonists(Integrin alpha-4/beta-7 antagonists)

Therapeutic Areas

Immune System DiseasesDigestive System DisordersOther Diseases+ [2]

Active Indication

Ileal DiseasesCrohn's disease, active moderateCrohn's disease, active severe+ [9]

Inactive Indication

Acute Graft Versus Host DiseaseCeliac DiseaseCholangitis, Sclerosing+ [8]

Originator Organization

Millennium Pharmaceuticals, Inc.

Active Organization

Takeda Pharmaceutical Co., Ltd.Takeda Development Center Americas, Inc.Takeda Pharmaceuticals U.S.A., Inc.

+ [9]

Inactive Organization

Millennium Pharmaceuticals, Inc.

License Organization

Royalty Pharma PlcThe General Hospital Corp.

Drug Highest PhaseApproved

First Approval Date

United States (20 May 2014),

Colitis, UlcerativeCrohn Disease

RegulationOrphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Fast Track (United States)

Login to view timeline

Structure/Sequence

Sequence Code 9976148H

Source: *****

Sequence Code 13007748L

Source: *****

This article provides an overview of intestinal transplantation, focusing on perioperative management and the recognition and treatment of complications in the intensive care unit. The review aims to update intensivists with a comprehensive understanding of the care of intestinal transplant recipients.

Recent findings:

Despite advances in immunosuppression, donor graft preparation, perioperative care, and the management of complications such as rejection, graft-versus-host disease, and infection, graft and patient survival rates following intestinal transplantation have not improved over the past decade and remain inferior to those of other solid organ transplants. Although surgical techniques have largely remained unchanged, some transplant centers have reported performing intestinal transplantation without a stoma and utilizing preoperative embolization in selected cases.Recent updates in maintenance immunosuppression include the expanded use of less commonly employed agents as part of multimodal regimens such as mammalian target of rapamycin inhibitors and antimetabolites as well as the introduction of therapies not traditionally used for maintenance, including costimulatory blockade, interleukin-2 receptor blockade, and vedolizumab.

Summary:

In recipients of intestinal transplants, prompt identification of infections and complications such as rejection, posttransplant lymphoproliferative disorder, and graft-versus-host disease is essential. Early recognition and intervention are critical to preserving graft function and improving overall survival. Effective management of these perioperative challenges requires a multidisciplinary team approach, with intensivists playing a central role in achieving optimal outcomes.

01 Apr 2026·DEN open

Vedolizumab Induces Remission in Two Cases of Ulcerative Colitis With Upper Gastrointestinal Involvement

Article

Author: Yoshida, Hitoshi ; Katagiri, Atsushi ; Otoyama, Yumi ; Higuchi, Kensuke ; Nakatani, Shinya ; Suzuki, Norihiro ; Ohara, Jyun ; Fujiwara, Takahisa ; Kikuchi, Kazuo ; Yamazaki, Yuta

ABSTRACT:

Ulcerative colitis (UC) predominantly affects the colon; upper gastrointestinal involvement (UGI) has been reported, but no established treatments exist. We report two cases of UC with concomitant UGI that showed positive responses to vedolizumab therapy. Case 1 involved a 29‐year‐old man who developed continuous inflammation extending from the stomach to the jejunum 1 month after an initial UC diagnosis. Intravenous prednisolone provided clinical remission; however, maintenance therapy with oral azathioprine was unsuccessful. Vedolizumab was initiated. Three months later, esophagogastroduodenoscopy (EGD) and colonoscopy confirmed the resolution of inflammation. Case 2 involved a 19‐year‐old man diagnosed with UGI via endoscopy while being evaluated for nausea and fever during UC treatment. 5‐aminosalicylic acid and prednisolone therapies were ineffective; therefore, vedolizumab was administered. Three months later, EGD confirmed mucosal healing. Both patients have maintained clinical remission for >2 years. To our knowledge, this is the first report of UC with UGI involvement that was successfully treated with vedolizumab. These findings suggest that vedolizumab is effective and safe for UGI treatment.

04 Mar 2026·SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Liver enzyme alterations during pregnancy in IBD are not attributable to disease activity or medication

Article

Author: van Dop, Willemijn A. ; Prins, Jelmer R. ; Donker, Hylke C. ; Visschedijk, Marijn C. ; Tauber, Tjebbe ; Dijkstra, Gerard ; van Es, Bram ; van der Woude, C. Janneke ; Bouwknegt, Dianne G.

BACKGROUND:

Inflammatory bowel disease (IBD) is often diagnosed during reproductive age, requiring adequate management during pregnancy. Physiological changes during pregnancy affect liver enzymes, complicating interpretation in a population prone to liver test abnormalities. This study aims to investigate liver enzyme trends throughout pregnancy in women with IBD.

METHODS:

A retrospective cohort study was conducted in three Dutch university hospitals. Pregnant women with IBD were included; liver enzyme levels were analyzed throughout pregnancy using Bayesian modeling. The association between liver enzymes and IBD disease activity, medication, pregnancy and adverse pregnancy outcomes was assessed, with estimated marginal means (EMMs) reported across trimesters and clinical subgroups.

RESULTS:

Liver enzyme levels exhibited significant trimester-specific variations in pregnant individuals with IBD. Levels of aminotransferases, γ-glutamyl transferase (γGT) and bilirubin generally declined, particularly in the second trimester, whereas alkaline phosphatase (ALP) levels increased markedly in the third trimester, mirroring physiological changes observed in healthy pregnancies. Adverse pregnancy outcomes were not associated with differences in liver enzyme levels. Several medications - particularly ustekinumab, vedolizumab, thiopurines, corticosteroids and amino salicylates - were associated with liver enzyme values or interacted with pregnancy, modulating the direction or magnitude of change. However, these effects were generally modest and remained within reference values.

CONCLUSIONS:

In pregnant women with IBD, changes in liver enzyme levels reflect physiological gestational adaptations rather than pharmacologic effects. Although medication-specific interactions were detected, their clinical significance appears limited. Marked elevations in liver enzymes during pregnancy cannot routinely be attributed to IBD activity or medication and warrant urgent analysis.

260

News (Medical) associated with Vedolizumab

24 Apr 2026

·www.biospace.com

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion INCHEON, Korea--(BUSINESS WIRE)-- #ADC --Third paragraph, second sentence of release should read: Revenue and operating profit in the first quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively. (instead of Revenue and operating profit in the fourth quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively.). The updated release reads: SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10 th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KRW 454.9 billion with an operating profit of KRW 144.0 billion. Revenue and operating profit in the first quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively. First quarter growth surpassed the January 2025 guidance by more than 10%, reflecting stronger-than-expected performance across the business. Samsung Epis Holdings posted a consolidated revenue of KRW 453.9 billion and operating profit of KRW 90.5 billion. Non-cash accounting adjustments, including amortization of purchase price allocation (PPA)-related development costs, are reflected in consolidated revenue and operating profit, following a consolidated revenue of KRW 251.7 billion and operating loss of KRW 63.6 billion in November and December 2025. [Samsung Bioepis Earnings, KRW billion] Q1’24 Q1’25 Q1’26 YoY Change Revenue 280.1 400.6 454.9 +54.3 (+14%) Operating Profit 38.1 127.9 144.0 +16.1 (+13%) Business Updates In October 2025, Samsung Bioepis entered into a private label partnership with CVS Caremark, the Pharmacy Benefit Manager (PBM) division of CVS Health, for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia 1 . BENEPALI™ (etanercept), Samsung Bioepis’ first biosimilar in Europe, continues to maintain its leadership position in the market as it celebrates its 10 th anniversary in Europe. In March, Samsung Bioepis expanded its development and commercialization partnership with Sandoz, on up to five biosimilar candidates including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), in multiple markets. Also in March, a Phase 1 first-in-human clinical trial for Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate, SBE303, has begun. Following the announcement, the company also presented a poster presentation of its nonclinical data at the American Association for Cancer Research (AACR) 2026 on April 20 th which demonstrates its encouraging efficacy, safety, tolerability and a promising ability to work in combination with existing immuno-oncology therapies. Samsung Bioepis’s second novel ADC candidate, SBE313, is currently in nonclinical development in collaboration with Phrontline Biopharma. Disclaimer This document contains ‘forward-looking statements’ regarding future expectations, projections, plans, and anticipation. ‘Forward-looking statements’ are matters that pertain to the Company’s future business and financial performance, and are subject to uncertainties such as trends in domestic and international financial markets, including but not limited to fluctuations in exchange rates and/or interest rates. ‘Forward-looking statements,’ by their nature, addresses matters that may be uncertain; actual results may be materially different from those expressed in this document. About Samsung Epis Holdings Co., Ltd. As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value through proactive R&D and investment and optimize business strategies for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings continues to embrace future challenges and drive innovation by identifying new growth drivers and strengthening global collaboration platforms, thereby laying a solid foundation for the continued growth of its subsidiaries. For more information about Samsung Epis Holdings, please visit: . About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit and follow us on LinkedIn and X . About Epis NexLab Co., Ltd. Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab is focused on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Epis NexLab, please visit: . Reference 1 Prolia is a registered trademark of Amgen Inc. Contacts Media Contact Yoon Kim, yoon1.kim@samsung.com Anna Nayun Kim, nayun86.kim@samsung.com

Financial StatementPhase 1

23 Apr 2026

·www.biospace.com

Samsung Epis Holdings Reports First Quarter 2026 Financial Results

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion INCHEON, Korea--(BUSINESS WIRE)-- #ADC --Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10 th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KRW 454.9 billion with an operating profit of KRW 144.0 billion. Revenue and operating profit in the fourth quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively. First quarter growth surpassed the January 2025 guidance by more than 10%, reflecting stronger-than-expected performance across the business. Samsung Epis Holdings posted a consolidated revenue of KRW 453.9 billion and operating profit of KRW 90.5 billion. Non-cash accounting adjustments, including amortization of purchase price allocation (PPA)-related development costs, are reflected in consolidated revenue and operating profit, following a consolidated revenue of KRW 251.7 billion and operating loss of KRW 63.6 billion in November and December 2025. [Samsung Bioepis Earnings, KRW billion] Q1’24 Q1’25 Q1’26 YoY Change Revenue 280.1 400.6 454.9 +54.3 (+14%) Operating Profit 38.1 127.9 144.0 +16.1 (+13%) Business Updates In October 2025, Samsung Bioepis entered into a private label partnership with CVS Caremark, the Pharmacy Benefit Manager (PBM) division of CVS Health, for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia 1 . BENEPALI™ (etanercept), Samsung Bioepis’ first biosimilar in Europe, continues to maintain its leadership position in the market as it celebrates its 10 th anniversary in Europe. In March, Samsung Bioepis expanded its development and commercialization partnership with Sandoz, on up to five biosimilar candidates including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), in multiple markets. Also in March, a Phase 1 first-in-human clinical trial for Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate, SBE303, has begun. Following the announcement, the company also presented a poster presentation of its nonclinical data at the American Association for Cancer Research (AACR) 2026 on April 20 th which demonstrates its encouraging efficacy, safety, tolerability and a promising ability to work in combination with existing immuno-oncology therapies. Samsung Bioepis’s second novel ADC candidate, SBE313, is currently in nonclinical development in collaboration with Phrontline Biopharma. Disclaimer This document contains ‘forward-looking statements’ regarding future expectations, projections, plans, and anticipation. ‘Forward-looking statements’ are matters that pertain to the Company’s future business and financial performance, and are subject to uncertainties such as trends in domestic and international financial markets, including but not limited to fluctuations in exchange rates and/or interest rates. ‘Forward-looking statements,’ by their nature, addresses matters that may be uncertain; actual results may be materially different from those expressed in this document. About Samsung Epis Holdings Co., Ltd. As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value through proactive R&D and investment and optimize business strategies for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings continues to embrace future challenges and drive innovation by identifying new growth drivers and strengthening global collaboration platforms, thereby laying a solid foundation for the continued growth of its subsidiaries. For more information about Samsung Epis Holdings, please visit: . About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit and follow us on LinkedIn and X . About Epis NexLab Co., Ltd. Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab is focused on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Epis NexLab, please visit: . Reference 1 Prolia is a registered trademark of Amgen Inc. Contacts Media Contact Yoon Kim, yoon1.kim@samsung.com Anna Nayun Kim, nayun86.kim@samsung.com

Phase 1Financial Statement

20 Apr 2026

·www.fiercebiotech.com

Odyssey charts fresh voyage to public markets after abandoning IPO plans last year

Odyssey sailed into April with $175.7 million still in the bank.\n In another sign that the biotech IPO market is heating back up, Odyssey Therapeutics has made a fresh announcement of its intention to go public.The autoimmune- and inflammatory-disease-focused biotech first disclosed an ambition to go public in January 2025 as part of a mini-wave of like-minded drug developers. But the biotech bailed on this ambition five months later as the IPO waters froze over, with Odyssey’s leadership concluding the move was “not in the best interests of the company … at this time.”Now, Odyssey is ready to re-embark on that voyage to the Nasdaq, according to an April 17 filing with the Securities and Exchange Commission.While the Boston-based biotech has yet to set out how many shares it will offer or at what price, Odyssey has made clear that top of the list of spending priorities will be OD-001. The RIPK2 inhibitor is undergoing phase 2 trials for ulcerative colitis as a monotherapy and in combination with Takeda’s Entyvio.The company will also use some of the cash to take its preclinical SLC15A4 program into a phase 1/2a trial, as well as “fund additional discovery, preclinical and clinical activities for disclosed or future programs,” it said in the filing.The company is led by Gary Glick, Ph.D., who previously spun immune-oncology startup Lycera out of his University of Michigan lab before later licensing Lycera’s assets to Celgene. Aside from Odyssey, Glick also cofounded and led IFM Therapeutics, which he departed in 2019 after deals with Bristol Myers Squibb and Novartis; and cofounded and ran Scorpion Therapeutics, which was later acquired by Eli Lilly for $2.5 billion in January 2025.Odyssey began its journey in 2021 with OrbiMed as the company’s biggest backer. Carl Gordon, Ph.D., a managing partner at the venture capital firm, called Glick and offered to fund anything he wanted to do.Since then, Odyssey has had no problems bringing in the megarounds. As well as the $218 million that the company launched with, the biotech has raised a $168 million series B in 2022, a $101 million series C in 2023 and a $123 million series D in September 2025.Of the combined $726.5 million that Odyssey has raised to date, the biotech entered April with $175.7 million still in the bank, according to Friday’s filing. Glick told Fierce last year that boosting the company’s preclinical pipeline is a key part of the strategy.“It was very important to the company and important to the board that we simply didn\'t just turn into a clinical development organization,” Glick said at the time of the September 2025 fundraise. “We built an amazing discovery team here, and we wanted to make sure that we\'re able to allocate the right amount of capital to early programs, while still rapidly advancing the clinical pipeline.”Odyssey’s renewed interest in an IPO reflects a broader industry trend. While a resurgence in listings earlier this year appeared to stall in March, Kailera Therapeutics re-energized the scene when the obesity biotech posted an industry-record-breaking $625 million IPO on Friday. Meanwhile, the likes of neuroscience-focused Seaport Therapeutics and blood-clotting company Hemab Therapeutics have both recently disclosed ambitions to go public.

IPOPhase 2Acquisition

100 Deals associated with Vedolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08083	Vedolizumab	L04AA33	DB09033

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Ileal Diseases	South Korea	Takeda Pharmaceuticals Korea Co., Ltd.	19 Jun 2015
Crohn's disease, active moderate	European Union	Takeda Pharma A/S	22 May 2014
Crohn's disease, active moderate	Iceland	Takeda Pharma A/S	22 May 2014
Crohn's disease, active moderate	Liechtenstein	Takeda Pharma A/S	22 May 2014
Crohn's disease, active moderate	Norway	Takeda Pharma A/S	22 May 2014
Crohn's disease, active severe	European Union	Takeda Pharma A/S	22 May 2014
Crohn's disease, active severe	Iceland	Takeda Pharma A/S	22 May 2014
Crohn's disease, active severe	Liechtenstein	Takeda Pharma A/S	22 May 2014
Crohn's disease, active severe	Norway	Takeda Pharma A/S	22 May 2014
Pouchitis	European Union	Takeda Pharma A/S	22 May 2014
Pouchitis	Iceland	Takeda Pharma A/S	22 May 2014
Pouchitis	Liechtenstein	Takeda Pharma A/S	22 May 2014
Pouchitis	Norway	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active moderate	European Union	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active moderate	Iceland	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active moderate	Liechtenstein	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active moderate	Norway	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active severe	European Union	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active severe	Iceland	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active severe	Liechtenstein	Takeda Pharma A/S	22 May 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pediatric Crohn's Disease	Phase 3	United States	Takeda Pharmaceutical Co., Ltd.	10 Feb 2022
Pediatric Crohn's Disease	Phase 3	China	Takeda Pharmaceutical Co., Ltd.	10 Feb 2022
Pediatric Crohn's Disease	Phase 3	Japan	Takeda Pharmaceutical Co., Ltd.	10 Feb 2022
Pediatric Crohn's Disease	Phase 3	Australia	Takeda Pharmaceutical Co., Ltd.	10 Feb 2022
Pediatric Crohn's Disease	Phase 3	Belgium	Takeda Pharmaceutical Co., Ltd.	10 Feb 2022
Pediatric Crohn's Disease	Phase 3	Canada	Takeda Pharmaceutical Co., Ltd.	10 Feb 2022
Pediatric Crohn's Disease	Phase 3	Croatia	Takeda Pharmaceutical Co., Ltd.	10 Feb 2022
Pediatric Crohn's Disease	Phase 3	Czechia	Takeda Pharmaceutical Co., Ltd.	10 Feb 2022
Pediatric Crohn's Disease	Phase 3	Greece	Takeda Pharmaceutical Co., Ltd.	10 Feb 2022
Pediatric Crohn's Disease	Phase 3	Hungary	Takeda Pharmaceutical Co., Ltd.	10 Feb 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03196427 (CTgov)	Phase 2	Pediatric Crohn's Disease \| Crohn Disease \| Colitis, Ulcerative	59	Vedolizumab (UC Participants (< 30 kg): Vedolizumab 100 mg)	ohgyodacwz = cwugkdjemg wtjiswrxsm (cghzhgbpyv, xqeuajnafb - fqlgcsfbcd) View more	-	13 Mar 2026
				Vedolizumab (UC Participants (< 30 kg): Vedolizumab 200 mg)	ohgyodacwz = vpjlsulpwo wtjiswrxsm (cghzhgbpyv, erkyjekfmi - pgreuicbeu) View more
NCT06732804 (AVT80-GL-P01, Company_Website) Manual	Phase 1	-	-	AVT80	uqqziatpax(lsuyptwuth) = Achieving the endpoint npjpreezrx (talrftmdtm ) Met	Positive	05 Feb 2026
				Vedolizumab
NCT06257706 (VECTORS, Pubmed \| BMJ Open Gastroenterol)	Phase 4	Perianal fistula due to Crohn's disease	304	Vedolizumab (Treatment target group 1)	rtcjwigmfh(nnixsrioxi) = pvouzfnvea zrfiilrxzz (lbggaautst )	Positive	01 Feb 2026
				Vedolizumab (Treatment target group 2)	mhnqoerxga(hohqapbpzb) = gtlunifcqi yqlkznzrvn (nyjmmnrfhu ) View more
ASH2025	Not Applicable	Steroid Refractory Graft Versus Host Disease	69	Vedolizumab + basiliximab	bnkjggusrz(jgbmmasstc) = einhtehcjv kqhyicrvps (pryohxyuje ) View more	Positive	06 Dec 2025
NCT06227910 (VICTRIVA, Pubmed \| Contemp Clin Trials Commun)	Phase 3	Crohn Disease	396	Vedolizumab + Upadacitinib	ydffpcmauc(mtbnqgzsvi) = fhscfzjmdu atnveccsqn (iplrfweeoe ) View more	Positive	01 Dec 2025
				Vedolizumab	gdleabcago(dylwnqirwh) = mjplxcecxm pqwlnyithm (wxzfudqqji ) View more
NCT03142321 (CTgov)	Phase 4	Enteritis \| Crohn Disease	48	Vedolizumab 300 MG Injection [Entyvio]	ygfvmxrlkj = ljskezezaf zzpfgeslwf (ommgfgzhdc, wversslhdn - ootlivwkdg) View more	-	17 Sep 2025
NCT02620046 (CTgov)	Phase 3	Crohn Disease \| Colitis, Ulcerative	746	Vedolizumab SC (Ulcerative Colitis: Vedolizumab 108 mg)	wavedoabhq = djhwhxdlmp ayfzsttxyk (bzvrxqivoz, wkrlgzvejc - ddfzeecqqs) View more	-	03 Apr 2025
				Vedolizumab SC (Crohn's Disease: Vedolizumab 108 mg)	wavedoabhq = lozaildgak ayfzsttxyk (bzvrxqivoz, fzmdjbeuwi - ycbhyqwuag) View more
NCT02862132 (VEDOKIDS, Pubmed \| Lancet Gastroenterol Hepatol)	Not Applicable	Inflammatory Bowel Diseases Maintenance	137	Vedolizumab	eqfzljzead(ykgijlzeyb) = dkbxzvopra bpqttibrtj (yerktvpzvt ) View more	Positive	01 Mar 2025
ChiCTR2200063233 (Early CD, PRNewswire) Manual	Phase 4	Crohn Disease	172	维得利珠单抗	cdcfzsnraz(sbwzmmrcll) = cbmwzrfmgt zmnzvikkvo (wpcgfgogsk ) View more	Positive	21 Feb 2025
NCT04804540 (CTgov)	Phase 4	Crohn Disease \| Colitis, Ulcerative	150	Vedolizumab (UC Participants: Vedolizumab 300 mg)	pwpsdvyfpk = cwzafsurhl zcvhgpuirv (azpsnbcgei, lhptqddzei - ehidgcqmfi) View more	-	12 Feb 2025
				Vedolizumab (CD Participants: Vedolizumab 300 mg)	pwpsdvyfpk = rfyzuocpls zcvhgpuirv (azpsnbcgei, iglsghayxn - swkgphqxau) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data